Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Digoxin Coadministered with PEX168 in Healthy Adults
NCT02472236Phase 1Completed
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Composite measure the plasma concentrations of Digoxin. Started Jun 2015; status: completed.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02472236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472236.